Chiesi Farmaceutici Spa, a Parma, Italy-based research-focused healthcare group, has signed a definitive agreement for the acquisition of Atopix Therapeutics Limited, an Oxford, UK-based clinical stage biotechnology company developing novel treatments for asthma.
Under the terms of the agreement, Chiesi will acquire all outstanding shares of Atopix, its assets and business for a total amount, inclusive of development, regulatory and commercial milestones, that could exceed €75m.
The acquisition of Atopix includes:
– OC459, an orally-adminstered CRTh2 antagonist currently in Phase 2 trials to evaluate the clinical benefit in patients with severe asthma who have persistent airway eosinophilia, despite treatment with high doses of inhaled corticosteroids and
– ATX2417, a back-up candidate, which has completed a Phase 1 human safety study.
The acquisition aims to enhance Chiesi’s pipeline in respiratory disorders, particularly in eosinophilic airways diseases.
Led by Tim Edwards, Executive Chairman, Atopix was backed by SR One, Wellington Partners, SV Life Sciences and MPM Capital.